BioStem grows hospital revenue again, raises 2026 revenue outlook
BioStem Technologies posted $7.6 million in third-quarter 2026 net revenue, cut its cash to $1.0 million, and raised full-year guidance to $28-29 million.
BioStem Technologies reported third-quarter 2026 results on November 12, 2026, saying hospital revenue was $6.8 million compared to $6.7 million in the second quarter of 20261. The company said the number of customers buying two or more of its product lines grew 14% from the second quarter1, and that customers purchasing three or more lines increased more than 40%1.
On manufacturing, BioStem said technology transfer of Neox and Clarix manufacturing to the Company's Pompano Beach facility is on track, with in-house production expected to begin in the first half of 20271. The company also said it finished combining back-office functions tied to its BioTissue relationship, with its CRM platform now live and integrated with its ERP system1, and that it added the VENDAJE product family to the Company's two largest existing GPO agreements in September1.
On clinical work, BioStem said top-line results from the Company's VLU study are scheduled to be reported at the Innovations in Wound Healing meeting in early December1.
Financially, the company raised guidance, saying it now expects full year 2026 revenue in the range of $28 million to $29 million, up from the prior outlook of $26 million to $29 million1. Cash fell sharply: cash and cash equivalents totaled $1.0 million as of September 30, 2026, compared to $7.0 million as of June 30, 20261, with cash used in operations in the third quarter of $8.8 million, versus $5.5 million in the second quarter1. To address liquidity, BioStem said it closed a private placement on September 30, 2026 with gross proceeds of approximately $3 million, with potential for up to approximately $5.6 million in additional gross proceeds from warrant exercises priced at $3.83 per share1, and separately said it is working with BioTissue to restructure the terms of the $10.0 million Clearance Payment in order to lower near-term cash obligations1. The company also said it is finalizing a cost reduction plan expected to reduce annualized cash operating expenses by approximately $10 to $12 million compared with the current run rate, with the full benefit beginning in the first quarter of 20271.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.